Register | Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC

Specialties >>

AML
Bladder Cancer
Breast Cancer
CAR T-Cell Therapy
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
Genomic Testing
GI Cancers
GIST
Gynecologic Cancers
HCC
Head & Neck Cancers
Hematology
HER2-Negative Breast Cancer
Immunotherapy
Liquid Biopsies
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Skin Cancers
Thyroid Cancers
More >>

Partners >>

Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up

Targeted Therapies in Oncology
October 2 2019

Clinical Articles

Patients With Rare Gene Fusion NRG1 Respond to Afatinib in NSCLC
Expert Reports Mixed Results in Interim Analysis for Multiarm NSCLC Trial
Treating ALL With Cellular and Targeted Immunotherapies Reduces the Need for Transplant
Patients With Small Cell Lung Cancer Experience Tumor Response With Liposomal Irinotecan
Identification of Certain Tumor Characteristics Enhances Immunotherapy Response in NSCLC
Advances From the World Conference on Lung Cancer and New Developments in Relapsed Lymphoma and Immunotherapy
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.